Screening for Autoantibodies in Type 1 Diabetes

Opinion
Video

Panelists discuss how screening for autoantibodies can help identify individuals at risk for type 1 diabetes before symptoms develop, enabling earlier intervention and potentially delaying disease onset.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
      Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Related Content
      Massive Trump Administration Cuts to Federal Grants Halt National Diabetes Prevention Program / image credit ©Centers for Disease Control and Prevention

      Massive Trump Administration Cuts to Federal Grants Halt National Diabetes Prevention Program

      March 19th 2025
      Article

      The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.

      Obesity & Type 2 Diabetes: An Expert Discussion

      Obesity & Type 2 Diabetes: An Expert Discussion

      Sydney Jennings
      June 30th 2023
      Podcast

      In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

      Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care

      Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care

      Sydney Jennings
      March 14th 2025
      Article

      The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Sydney Jennings
      July 22nd 2022
      Podcast

      "Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

      FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

      FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

      Patient Care Editorial Staff
      February 14th 2025
      Article

      Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

      Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose / image credit: ©New Africa/AdobeStock

      Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

      Sydney Jennings
      February 13th 2025
      Article

      Your daily dose of the clinical news you may have missed.

      © 2025 MJH Life Sciences

      All rights reserved.